Johnson & Johnson (JNJ): Shareholders' Equity
$81.54B
As of 2025-12-28
$81.53B
As of 2026-09-27
+2.0%
3-year compound annual growth
+5.2%
5-year compound annual growth
+1.4%
10-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-28 | $81.54B | +14.1% | 2026-02-11, Balance as of period end |
| 2024-12-29 | $71.49B | +3.9% | 2026-02-11, Balance as of period end |
| 2023-12-31 | $68.77B | -10.5% | 2026-02-11, Balance as of period end |
| 2023-01-01, Fiscal 2022 | $76.80B | +3.8% | 2025-02-13, Balance as of period end |
| 2022-01-02, Fiscal 2021 | $74.02B | +17.0% | 2024-02-16, Balance as of period end |
| 2021-01-03, Fiscal 2020 | $63.28B | +6.4% | 2023-02-16, Balance as of period end |
| 2019-12-29 | $59.47B | -0.5% | 2022-02-17, Balance as of period end |
| 2018-12-30 | $59.75B | -0.7% | 2021-02-22, Balance as of period end |
| 2017-12-31 | $60.16B | -14.6% | 2020-02-18, Balance as of period end |
| 2017-01-01, Fiscal 2016 | $70.42B | -1.0% | 2019-02-20, Balance as of period end |
| 2016-01-03, Fiscal 2015 | $71.15B | +2.0% | 2018-02-21, Balance as of period end |
| 2014-12-28 | $69.75B | -5.8% | 2017-02-27, Balance as of period end |
| 2013-12-29 | $74.05B | +14.2% | 2016-02-24, Balance as of period end |
| 2012-12-30 | $64.83B | +13.6% | 2015-02-24, Balance as of period end |
| 2012-01-01, Fiscal 2011 | $57.08B | +0.9% | 2014-02-21, Balance as of period end |
| 2011-01-02, Fiscal 2010 | $56.58B | +11.8% | 2013-02-22, Balance as of period end |
| 2010-01-03, Fiscal 2009 | $50.59B | +19.0% | 2012-02-23, Balance as of period end |
| 2008-12-28 | $42.51B | -1.9% | 2011-02-25, Balance as of period end |
| 2007-12-30 | $43.32B | n/a | 2010-03-01, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Johnson & Johnson (JNJ) | 2025-12-28 | $81.54B | +14.1% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $26.54B | +85.9% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $52.66B | +13.6% |
| Pfizer Inc (PFE) | 2025-12-31 | $86.78B | -1.9% |
| AbbVie Inc. (ABBV) | 2025-12-31 | -$3.27B | n/m |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $18.47B | +13.1% |
| Abbott Laboratories (ABT) | 2025-12-31 | $52.13B | +9.4% |
| Teva Pharmaceutical Industries Ltd (TEVA) | 2025-12-31 | $7.91B | +47.1% |
| Regeneron Pharmaceuticals, Inc. (REGN) | 2025-12-31 | $31.26B | +6.5% |
Compare JNJ, LLY, MRK, PFE side by side · Screen every company in Pharmaceutical Preparations ↗